Benchmarking Deep Graph Generative Models for Optimizing New Drug Molecules for COVID-19
arXiv:2102.04977
Abstract
Design of new drug compounds with target properties is a key area of research in generative modeling. We present a small drug molecule design pipeline based on graph-generative models and a comparison study of two state-of-the-art graph generative models for designing COVID-19 targeted drug candidates: 1) a variational autoencoder-based approach (VAE) that uses prior knowledge of molecules that have been shown to be effective for earlier coronavirus treatments and 2) a deep Q-learning method (DQN) that generates optimized molecules without any proximity constraints. We evaluate the novelty of the automated molecule generation approaches by validating the candidate molecules with drug-protein binding affinity models. The VAE method produced two novel molecules with similar structures to the antiretroviral protease inhibitor Indinavir that show potential binding affinity for the SARS-CoV-2 protein target 3-chymotrypsin-like protease (3CL-protease).
References in corpus (7)
- Playing Atari with Deep Reinforcement Learning
- Neural Message Passing for Quantum Chemistry
- Junction Tree Variational Autoencoder for Molecular Graph Generation
- DeepPurpose: a Deep Learning Library for Drug-Target Interaction Prediction
- SMILES Enumeration as Data Augmentation for Neural Network Modeling of Molecules
- Grammar Variational Autoencoder
- Screening of Therapeutic Agents for COVID-19 using Machine Learning and Ensemble Docking Simulations